CH Biotech R&D Co., Ltd. (TPE:6534)
Taiwan
· Delayed Price · Currency is TWD 93.40
-2.50 (-2.61%)
Apr 29, 2026, 1:30 PM CST
CH Biotech R&D Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 1,819 | 1,636 | 1,515 | 1,434 | 1,019 | Upgrade
|
| Revenue Growth (YoY) | 11.21% | 7.98% | 5.63% | 40.81% | 45.05% | Upgrade
|
| Cost of Revenue | 292.36 | 270.92 | 254.73 | 299.52 | 170.56 | Upgrade
|
| Gross Profit | 1,527 | 1,365 | 1,260 | 1,135 | 847.95 | Upgrade
|
| Selling, General & Admin | 485.79 | 459.16 | 389 | 351.12 | 267.2 | Upgrade
|
| Research & Development | 406.72 | 363.36 | 305.24 | 272.41 | 221.48 | Upgrade
|
| Operating Expenses | 903.69 | 822.52 | 694.24 | 623.54 | 488.68 | Upgrade
|
| Operating Income | 623.13 | 542.3 | 565.86 | 511.06 | 359.27 | Upgrade
|
| Interest Expense | -16.96 | -15 | -16.81 | -16.81 | -13.9 | Upgrade
|
| Interest & Investment Income | 11.33 | 18.8 | 17.22 | 5.12 | 0.6 | Upgrade
|
| Earnings From Equity Investments | -3.1 | -0.26 | -0.05 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -50.36 | 39.58 | 7.18 | 62.28 | -12.15 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.35 | 5.54 | 4.46 | 3.59 | 25.69 | Upgrade
|
| EBT Excluding Unusual Items | 569.4 | 590.96 | 577.86 | 565.23 | 359.5 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.52 | 0.31 | 1.07 | 0.57 | 0.11 | Upgrade
|
| Other Unusual Items | - | 1.69 | - | - | 0.04 | Upgrade
|
| Pretax Income | 568.87 | 592.96 | 578.93 | 565.8 | 359.65 | Upgrade
|
| Income Tax Expense | 105.09 | 117.27 | 115.64 | 100.37 | 68.15 | Upgrade
|
| Earnings From Continuing Operations | 463.79 | 475.69 | 463.29 | 465.42 | 291.5 | Upgrade
|
| Minority Interest in Earnings | 0.21 | 0.7 | - | - | - | Upgrade
|
| Net Income | 464 | 476.39 | 463.29 | 465.42 | 291.5 | Upgrade
|
| Net Income to Common | 464 | 476.39 | 463.29 | 465.42 | 291.5 | Upgrade
|
| Net Income Growth | -2.60% | 2.83% | -0.46% | 59.66% | 191.03% | Upgrade
|
| Shares Outstanding (Basic) | 103 | 103 | 97 | 97 | 97 | Upgrade
|
| Shares Outstanding (Diluted) | 103 | 103 | 98 | 99 | 98 | Upgrade
|
| Shares Change (YoY) | -0.05% | 5.50% | -0.77% | 0.54% | 0.44% | Upgrade
|
| EPS (Basic) | 4.51 | 4.63 | 4.76 | 4.79 | 3.00 | Upgrade
|
| EPS (Diluted) | 4.50 | 4.61 | 4.73 | 4.72 | 2.97 | Upgrade
|
| EPS Growth | -2.39% | -2.54% | 0.21% | 58.92% | 189.44% | Upgrade
|
| Free Cash Flow | 465.68 | -49.98 | 545.47 | 585.08 | 192.43 | Upgrade
|
| Free Cash Flow Per Share | 4.51 | -0.48 | 5.57 | 5.93 | 1.96 | Upgrade
|
| Dividend Per Share | 4.800 | 4.100 | 4.090 | 3.880 | 1.304 | Upgrade
|
| Dividend Growth | 17.07% | 0.24% | 5.41% | 197.48% | 199.98% | Upgrade
|
| Gross Margin | 83.93% | 83.44% | 83.18% | 79.11% | 83.25% | Upgrade
|
| Operating Margin | 34.25% | 33.15% | 37.35% | 35.64% | 35.27% | Upgrade
|
| Profit Margin | 25.51% | 29.12% | 30.58% | 32.45% | 28.62% | Upgrade
|
| Free Cash Flow Margin | 25.60% | -3.06% | 36.01% | 40.80% | 18.89% | Upgrade
|
| EBITDA | 807.37 | 704.78 | 703.17 | 628.06 | 435.89 | Upgrade
|
| EBITDA Margin | 44.38% | 43.09% | 46.42% | 43.79% | 42.80% | Upgrade
|
| D&A For EBITDA | 184.24 | 162.48 | 137.31 | 117.01 | 76.62 | Upgrade
|
| EBIT | 623.13 | 542.3 | 565.86 | 511.06 | 359.27 | Upgrade
|
| EBIT Margin | 34.25% | 33.15% | 37.35% | 35.64% | 35.27% | Upgrade
|
| Effective Tax Rate | 18.47% | 19.78% | 19.98% | 17.74% | 18.95% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.